Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of
diabetes worldwide. The number affected is increasing rapidly with alarming trends
in children and young adults (up to age 40 years). Early detection and proactive management
are crucial for prevention and mitigation of microvascular and macrovascular complications
and mortality burden. Access to novel therapies improves person-centred outcomes beyond
glycaemic control. Precision medicine, including multiomics and pharmacogenomics,
hold promise to enhance understanding of disease heterogeneity, leading to targeted
therapies.